objobjobj, page-20

Surges, I would not be surprised to see GSK being our #1 financial contributor in 2011.

GSK's huge focus towards providing medicines to the poorer nations around the world blends perfectly for a minimal cost impact of the OBJ eM-patch

"GlaxoSmithKline Chief Andrew Witty has a plan to save the struggling drugmaker: Turn it into a collection of entrepreneurial biotech outfits."

"Glaxo has the best, the brightest, the most booming pipeline in the industry over the next three years," says UBS analyst Gbola Amusa. "Its lower U.S. exposure and higher emerging markets exposure is exactly what you want."

click here for Big Red Bio-tech blog - 04/01/2011

click here for forbes 17/12/2010 article